References
- Ruscitti P, Cipriani P, Ciccia F, Masedu F, Liakouli V, Carubbi F, et al. Prognostic factors of macrophage activation syndrome, at the time of diagnosis, in adult patients affected by autoimmune disease: analysis of 41 cases collected in 2 rheumatologic centers. Autoimmun Rev 2017;16:16–21.
- Kumakura S, Ishikura H, Munemasa S, Adachi T, Murakawa Y, Kobayashi S. Adult onset Still’s disease associated hemophagocytosis. J Rheumatol 1997;24:1645–8.
- Kumakura S, Murakawa Y. Clinical characteristics and treatment outcomes of autoimmune-associated hemophagocytic syndrome in adults. Arthritis Rheumatol 2014;66:2297–307.
- Kaneko Y, Kameda H, Ikeda K, Ishii T, Murakami K, Takamatsu H, et al. Tocilizumab in patients with adult-onset still’s disease refractory to glucocorticoid treatment: a randamised, double-blind, placebo-controlled phase III trial. Ann Rheum Dis 2018;77:1720–9.
- Loh NK, Lucas M, Femandez S, Prentice D. Successful treatment of macrophage activation syndrome complicating adult Still disease with anakinra. Intern Med J 2012;42:1358–62.
- Kobayashi M, Takahashi Y, Ymashita H, Kaneko H, Mimori A. Benefit and a possible risk of tocilizumab therapy for adult-onset Still’s disease accompanied by macrophage-activation syndrome. Mod Rheumatol 2011;21:92–6.
- Banse C, Vittecoq O, Benhamou Y, Gauthier-Prieur M, Lequerré T, Lévesque H. Reactive macrophage activation syndrome possibly triggered by canakinumab in a patient with adult-onset Still’s disease. Joint Bone Spine 2013;80:653–5.
- Ladhari C, Jorgensen C, Pers YM. Treatment of refractory adult onset Still’s disease with combination anakinra and baricitinib therapy. Rheumatology (Oxford) 2019;58:736–7.